Piobot V Tablet contains Pioglitazone 15mg and Vildagliptin 50mg, offering a dual-action therapy for effective glycemic control in type-2 diabetes mellitus. Pioglitazone enhances peripheral insulin sensitivity, while Vildagliptin inhibits DPP-4 to increase incretin levels, providing balanced blood sugar management.
This combination helps reduce both fasting and postprandial glucose levels, improving overall metabolic control. Its convenient oral dosage ensures patient adherence and consistent therapeutic outcomes, making it a preferred option for endocrinologists and diabetes specialists.
Piobot V Tablet is widely prescribed in outpatient clinics, hospital diabetes units, and endocrinology departments. Its dual mechanism of action ensures reliable efficacy for patients inadequately controlled on monotherapy or requiring combination therapy.
Adding Piobot V Tablet to your diabetes and metabolic-care portfolio strengthens your product range, creating opportunities in hospital supply, retail pharmacy distribution, institutional procurement, export markets, and third-party manufacturing. Its clinical significance ensures consistent demand and profitable performance for distributors.